Charles L. Sawyers, M.D.

Board member since 2013

Nationality: American | Year of birth: 1959

Charles L. Sawyers is a highly accomplished expert and leader in cancer research. As a physician and prominent scientist, he has a deep understanding of the benefits of drugs for patients and society at large, and the importance of access to medicines. Dr. Sawyers co-developed the Novartis cancer drug Gleevec/Glivec and has received numerous honors and awards, including the Lasker-DeBakey Clinical Medical Research Award.

Professional experience

  • Chair of the Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, US (2006–present)
  • Professor of medicine (2008–present), and professor of cell and developmental biology (2011–present), Weill Cornell Graduate School of Medical Sciences, US
  • Investigator, Howard Hughes Medical Institute, US (2002–2006 and 2008–present)
  • Associate chief, Division of Hematology-Oncology, University of California, Los Angeles, US (1996–2006)


  • Member, National Academy of Medicine, US
  • Member, National Academy of Sciences, US
  • Investigator, Howard Hughes Medical Institute, US
  • Science advisor for the following US companies: Arsenal Capital Partners; BeiGene Ltd.; Blueprint Medicines Corp.; Foghorn Therapeutics Inc.; Housey Pharmaceutical Research Laboratories; KSQ Therapeutics Inc.; Nextech Invest Ltd.; ORIC Pharmaceuticals Inc.; PMV Pharmaceuticals Inc.; The Column Group
  • Member, National Cancer Advisory Board, US (2012–2020)
  • President, American Association for Cancer Research, US (2013–2014)


  • Doctor of medicine, Johns Hopkins University School of Medicine, US
  • Bachelor of Arts, Princeton University, US

Key skills

  • Medicine/healthcare/R&D
  • Leadership/management
  • Environmental, social and governance (ESG)